NOVO NORDISK: OVERALL DEMAND WILL CONTINUE TO EXCEED SUPPLY WHICH MEANS THAT SOME PATIENTS MAY STILL HAVE DIFFICULTY FILLING WEGOVY® PRESCRIPTIONS.
Novo Nordisk: Overall Demand Will Continue To Exceed Supply Whic…
![Reuters logo](/images/reuters.jpg)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
970 DKK | +0.26% |
|
-3.25% | +38.95% |
05:13pm | ETF of the week: Investing in strong trends with the momentum theme | ![]() |
02:53pm | NOVO NORDISK : Deutsche Bank remains its Buy rating | ZD |
NOVO NORDISK: OVERALL DEMAND WILL CONTINUE TO EXCEED SUPPLY WHICH MEANS THAT SOME PATIENTS MAY STILL HAVE DIFFICULTY FILLING WEGOVY® PRESCRIPTIONS.
1st Jan change | Capi. | |
---|---|---|
+38.95% | 62TCr | |
+54.07% | 81TCr | |
-7.05% | 35TCr | |
+15.44% | 32TCr | |
+5.72% | 29TCr | |
+14.46% | 24TCr | |
-0.37% | 22TCr | |
+14.78% | 22TCr | |
+7.42% | 17TCr | |
-3.79% | 16TCr |